warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
TG Therapeutics UTX-TGR-204: A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Brief Description  
Primary: To determine the overall response rate (ORR) defined as the sum of complete responses (CR) and partial responses (PR). Secondary: To evaluate the progression-free survival (PFS) and duration of response (DOR). TO evaluate the percent of patients that achieve MRD negativity. TO evaluate the safety of ublituximab in combination with TGR-1202.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Leukemia, other
Status  
OPEN
Start Date  
12/05/2016
IRB Number  
00014332
Principal Investigator  
Jacobs, Ryan
Contact Name  
Sally P Ware

For More Information, Contact  Sally  P, Ware
Phone:  980-442-2030 Fax:    
Email:  Sally.Ware@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close